Direct-Acting Antivirals
DDAs, or direct-acting antivirals, are medications commonly used for treating hepatitis. These agents target HBV at various stages of its lifecycle. They usually come in tablet form and contain combinations of drugs that can effectively combat the virus. The three classes of these medications are NS3/4A, NS5A, and NS5B, and each of them attacks the condition in unique ways. Common drugs are Harvoini, Zepatier, Epclusa, Vosevia, and Mavyret.
Sovaldi was also approved by the FDA in 2013 and is readily available today. It’s Sofosbuvir’s brand name. This polymerase inhibitor is suitable for those with hepatitis but without liver diseases like cirrhosis. Healthcare providers often prescribe the medication alongside specific antiviral drugs like RBV. Other DAA agents are Daklinza, Olysio, and Viekira Pak. According to studies, direct-acting antivirals are effective and can treat or cure the condition in ninety percent of all cases.
The dosage of the treatment generally depends on the genotype that the patient has. It’s common for people to take them for eight to twenty-four weeks. The time that DAA agents usually take before treatment results show depends on which direct-acting antiviral the person takes. Moreover, some side effects it can cause are breathlessness, anemia, and nausea.
